TaiwanJ Pharmaceuticals Co., Ltd. (6549.TWO) develops and commercializes small-molecule therapeutics targeting chronic organ inflammation from metabolic, autoimmune, and infectious causes, with a focus on liver diseases, allergy, and asthma; its pipeline includes re-profiled approved drugs via the 505(b)(2) pathway such as JKB-122, a long-acting TLR4 antagonist for non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), autoimmune hepatitis (AIH), and liver fibrosis demonstrating anti-fibrotic, immuno-modulating, and anti-inflammatory effects, and JKB-121; novel chemical entities (NCEs) such as TJC-0265, an autotaxin inhibitor for NASH and idiopathic pulmonary fibrosis (IPF), TJC-0434, TJC-0545, and TJC-0667 addressing core technologies including TLR4, autotaxin, NOX, and HDAC for indications like kidney injury, inflammatory bowel disease, rheumatoid arthritis, asthma, and atopic dermatitis. The company operates primarily in Taiwan, seeking product development collaborations and strategic alliances to advance its pipeline. Founded in 2011 and headquartered in Zhubei City, Hsinchu County, Taiwan, TaiwanJ employs around 13 people and lists on the Taipei Exchange. Recent developments include reporting earnings for the half-year ended June 30, 2024, and ongoing Phase II clinical activities for key candidates like JKB-122, with no major acquisitions, funding rounds, or new partnerships announced in 2024 or 2025.